On 11 August 2016, NRT announced the submission of an IND application with the FDA. On 10 September 2016, NRT received a letter from the FDA advising that the study may proceed. Accordingly, NRT advised the note holders of this conversion event and a resolution of the directors of NRT was passed on 14 September 2016 approving the issue of 20,000,000 ordinary shares to the note holders. The ordinary shares are issued on 14 September 2016.
About Novogen Limited
Novogen Limited (ASX: NRT; NASDAQ: NVGN) is an oncology-focused biotechnology company based in Sydney, Australia. Novogen has two proprietary drug discovery platforms (superbenzopyrans and anti-tropomyosins) with the potential to yield first-in-class agents across a range of oncology indications. The three lead molecules Cantrixil, Anisina, and Trilexium are in preclinical development, with the most advanced molecule, Cantrixil, slated to enter clinical trials in late 2016. For more information, please visit: www.novogen.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/conversion-of-convertible-notes-300327696.html
SOURCE Novogen Limited